---
title: "HENLIUS's biosimilar HLX11 for patritumab has received a positive review opinion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277355752.md"
description: "HENLIUS announced that recently, the company's self-developed biosimilar of pertuzumab, HLX11, received a positive review opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of HLX11's marketing authorization application. The CHMP's review opinion will be submitted to the European Commission, which will make a final review decision in the next 2-3 months"
datetime: "2026-03-01T12:48:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277355752.md)
  - [en](https://longbridge.com/en/news/277355752.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277355752.md)
---

# HENLIUS's biosimilar HLX11 for patritumab has received a positive review opinion

HENLIUS (02696.HK) announced that recently, its self-developed biosimilar drug HLX11, a pertuzumab biosimilar, received a positive review opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of the marketing authorization application for HLX11. The CHMP's review opinion will be submitted to the European Commission, which will make a final review decision in the next 2-3 months

### Related Stocks

- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [02696.HK](https://longbridge.com/en/quote/02696.HK.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)

## Related News & Research

- [Henlius Biotech Doses First Patient in Breast Cancer Drug Study](https://longbridge.com/en/news/282326155.md)
- [CSPC wins China trial approval for SYS6051 in advanced solid tumors](https://longbridge.com/en/news/282818199.md)
- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [RemeGen Drug Approved For Cancer Indication](https://longbridge.com/en/news/282478668.md)
- [Sino Biopharmaceutical Unit Enrolls First Patient in Gastric Cancer Drug Trial](https://longbridge.com/en/news/282827241.md)